SCHEMBL23728355

SCHEMBL23728355

[CH]=CC(=O)c1ccc(O)cc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.59
CYP3A4 P08684 3/20 0.58
NFKB1 P19838 3/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
CYP2C9 P11712 2/20 0.58
CYP2C19 P33261 2/20 0.58
MAPT P10636 2/20 0.58
HPGD P15428 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
ALOX15 P16050 2/20 0.58
MAPK1 P28482 2/20 0.58
HSD17B10 Q99714 2/20 0.58
AKR1B1 P15121 2/20 0.58
CHRNA7 P36544 2/20 0.58
HSD17B2 P37059 2/20 0.58
NFKB2 Q00653 2/20 0.58
RELA Q04206 2/20 0.58
BACE1 P56817 2/20 0.58
TYR P14679 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11068235 0.83 CYP3A4 (0.72) CES2CYP3A4NFKB1MEN1KMT2A
SCHEMBL11068223 0.83 CYP3A4 (0.72) CES2CYP3A4NFKB1MEN1KMT2A
SCHEMBL30382876 0.79 CES2 (0.59) CES2CYP3A4NFKB1MEN1KMT2A
SCHEMBL11139626 0.79 CES2 (0.59) CES2CYP3A4NFKB1MEN1KMT2A
SCHEMBL17975267 0.76 CES2 (0.55) CES2CYP3A4NFKB1MEN1KMT2A
SCHEMBL14416840 0.76 CYP3A4 (0.64) CES2CYP3A4NFKB1MEN1KMT2A
SCHEMBL29357695 0.75 CES2 (0.73) CES2CYP3A4NFKB1MEN1KMT2A
SCHEMBL2156558 0.75 CES2 (1.00) CES2CYP3A4NFKB1MEN1KMT2A
SCHEMBL39507 0.75 CES2 (0.73) CES2CYP3A4NFKB1MEN1KMT2A
SCHEMBL25208375 0.75 MEN1 (0.96) CYP3A4NFKB1MEN1KMT2ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US disclosed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB CES2 726/4885CYP3A4 3571/4885NFKB1 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.